SCHEMBL648490

SCHEMBL648490

CCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc2c(c1)OCO2)Cc1ccc2c(c1)OCO2

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.62
MAPT P10636 4/20 0.46
KDM4E B2RXH2 4/20 0.46
TSHR P16473 3/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
CASP1 P29466 1/20 0.46
HSD17B10 Q99714 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
ALDH1A1 P00352 4/20 0.42
GAA P10253 3/20 0.42
HPGD P15428 3/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648830 0.92 C5AR1 (0.64) C5AR1MAPTKDM4ETSHRKMT2A
SCHEMBL652877 0.92 C5AR1 (0.66) C5AR1MAPTKDM4ETSHRKMT2A
SCHEMBL4767016 0.90 C5AR1 (0.75) C5AR1MAPTKDM4ETSHRKMT2A
SCHEMBL5135929 0.88 C5AR1 (0.72) C5AR1MAPTKDM4ETSHRKMT2A
SCHEMBL649255 0.88 C5AR1 (0.71) C5AR1MAPTKDM4ETSHRKMT2A
SCHEMBL650391 0.87 C5AR1 (0.59) C5AR1MAPTKDM4ETSHRKMT2A
SCHEMBL5136954 0.87 C5AR1 (0.60) C5AR1MAPTKDM4ETSHRKMT2A
SCHEMBL649645 0.87 C5AR1 (0.70) C5AR1MAPTKDM4ETSHRKMT2A
SCHEMBL648372 0.87 C5AR1 (0.70) C5AR1MAPTKDM4ETSHRKMT2A
SCHEMBL649446 0.86 C5AR1 (0.72) C5AR1MAPTKDM4ETSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116390691-A Self-assembled amphiphilic peptide hydrogels 歌尔4梅德股份有限公司 2023-07-04 CN claimed
CN-109154598-B Methods, systems, and compositions for studying solvent accessibility and three-dimensional structure of biomolecules 威斯康星校友研究基金会 2023-01-10 CN claimed
CN-114031718-A Solvent type dispersion resin for high solid content coating and preparation method thereof 上海金仕迈树脂有限公司 2022-02-11 CN claimed
CN-113181112-A Neuroactive steroid solutions and methods of their use 萨奇治疗股份有限公司 2021-07-30 CN claimed
CN-105377873-B Elucidation of ion exchange chromatography input optimization 豪夫迈·罗氏有限公司 2021-03-30 CN claimed
CN-112771378-B Health care management method 株式会社普欧威盖特 2024-07-05 CN disclosed
CN-115484957-B Formulations for treating ocular conditions 兰泰克生物技术公司 2024-06-21 CN disclosed
CN-118234867-A Compositions and methods for producing cyclic polyribonucleotides 旗舰创业创新六公司 2024-06-21 CN disclosed
CN-117923676-A Methods and compositions for reducing azole and AOX corrosion inhibitors BL 科技公司 2024-04-26 CN disclosed
CN-115667149-B Cerium oxide nanoparticle, dispersion containing cerium oxide nanoparticle, oxidizing agent, antiviral agent, and antibacterial agent 东丽株式会社 2024-03-08 CN disclosed
CN-117587645-A Reaction liquid for pigment printing and dyeing, ink set and recording method 精工爱普生株式会社 2024-02-23 CN disclosed
CN-117582496-A Antibody compositions 美勒斯公司 2024-02-23 CN disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
WO-2007145824-A2 SELF-FOAMING CEMENT FOR VOID FILLING AND/OR DELIVERY SYSTEMS KYPHON SARL (CH) 2007-12-21 WO disclosed
US-20070283849-A1 Self-foaming cement for void filling and/or delivery systems SANATIS GMBH (DE) 2007-12-13 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed